Title: 2 Sec. 16. Section 28-405, Revised Statutes Cumulative Supplement,
Official Title: 2 Sec. 16. Section 28-405, Revised Statutes Cumulative Supplement,
Number of Sections: 1
Source: versions - Riepe AM577
Media Type: application/pdf
Strikethrough Detection: 36 sections found

================================================================================

Section 1:
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
AMENDMENTS TO LB230
(Amendments to AM381)
Introduced by Riepe, 12.
1 1. Insert the following new sections:
3 2024, is amended to read:
4 28-405 The following are the schedules of controlled substances
5 referred to in the Uniform Controlled Substances Act, unless specifically
6 contained on the list of exempted products of the Drug Enforcement
7 Administration of the United States Department of Justice as the list
8 existed on January 31, 2022:
9 Schedule I
10 (a) Any of the following opiates, including their isomers, esters,
11 ethers, salts, and salts of isomers, esters, and ethers, unless
12 specifically excepted, whenever the existence of such isomers, esters,
13 ethers, and salts is possible within the specific chemical designation:
14 (1) Acetylmethadol;
15 (2) Allylprodine;
16 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
17 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
18 (4) Alphameprodine;
19 (5) Alphamethadol;
20 (6) Benzethidine;
21 (7) Betacetylmethadol;
22 (8) Betameprodine;
23 (9) Betamethadol;
24 (10) Betaprodine;
25 (11) Clonitazene;
26 (12) Dextromoramide;
-1-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (13) Difenoxin;
2 (14) Diampromide;
3 (15) Diethylthiambutene;
4 (16) Dimenoxadol;
5 (17) Dimepheptanol;
6 (18) Dimethylthiambutene;
7 (19) Dioxaphetyl butyrate;
8 (20) Dipipanone;
9 (21) Ethylmethylthiambutene;
10 (22) Etonitazene;
11 (23) Etoxeridine;
12 (24) Furethidine;
13 (25) Hydroxypethidine;
14 (26) Ketobemidone;
15 (27) Levomoramide;
16 (28) Levophenacylmorphan;
17 (29) Morpheridine;
18 (30) Noracymethadol;
19 (31) Norlevorphanol;
20 (32) Normethadone;
21 (33) Norpipanone;
22 (34) Phenadoxone;
23 (35) Phenampromide;
24 (36) Phenomorphan;
25 (37) Phenoperidine;
26 (38) Piritramide;
27 (39) Proheptazine;
28 (40) Properidine;
29 (41) Propiram;
30 (42) Racemoramide;
31 (43) Trimeperidine;
-2-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
2 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
3 piperidine;
4 (45) Tilidine;
5 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
6 phenylpropanamide, its optical and geometric isomers, salts, and salts of
7 isomers;
8 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
9 isomers, salts, and salts of isomers;
10 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
11 optical isomers, salts, and salts of isomers;
12 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
13 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
14 isomers;
15 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
16 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
17 of isomers;
18 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
19 its optical isomers, salts, and salts of isomers;
20 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
21 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
22 of isomers;
23 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
24 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
25 geometric isomers, salts, and salts of isomers;
26 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
27 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
28 salts, and salts of isomers;
29 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
30 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
31 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
-3-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 propanamide, its optical isomers, salts, and salts of isomers;
2 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
3 piperidinyl)propanamide, its optical isomers, salts, and salts of
4 isomers;
5 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
6 methylbenzamide;
7 (59) 4-Fluoroisobutyryl Fentanyl;
8 (60) Acetyl Fentanyl;
9 (61) Acyrloylfentanyl;
10 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
11 benzamide;
12 (63) Butyryl fentanyl;
13 (64) Cyclopentyl fentanyl;
14 (65) Cyclopropyl fentanyl;
15 (66) Furanyl fentanyl;
16 (67) Isobutyryl fentanyl;
17 (68) Isotonitazene;
18 (69) Methoxyacetyl fentanyl;
19 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
20 (71) Tetrahydrofuranyl fentanyl;
21 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
22 yl) propionamide;
23 (73) Ocfentanil;
24 (74) Ortho-Fluorofentanyl;
25 (75) Para-chloroisobutyryl fentanyl;
26 (76) Para-Fluorobutyryl Fentanyl;
27 (77) Valeryl fentanyl;
28 (78) Phenyl Fentanyl;
29 (79) Para-Methylfentanyl;
30 (80) Thiofuranyl Fentanyl;
31 (81) Beta-methyl Fentanyl;
-4-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (82) Beta'-Phenyl Fentanyl;
2 (83) Crotonyl Fentanyl;
3 (84) 2'-Fluoro Ortho-Fluorofentanyl;
4 (85) 4'-Methyl Acetyl Fentanyl;
5 (86) Ortho-Fluorobutyryl Fentanyl;
6 (87) Ortho-Methyl Acetylfentanyl;
7 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
8 (89) Ortho-Fluoroacryl Fentanyl;
9 (90) Fentanyl Carbamate;
10 (91) Ortho-Fluoroisobutyryl Fentanyl;
11 (92) Para-Fluoro Furanyl Fentanyl;
12 (93) Para-Methoxybutyryl Fentanyl;
13 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
14 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
15 (95) Fentanyl-related substances, their isomers, esters, ethers,
16 salts and salts of isomers, esters, and ethers. Unless specifically
17 excepted, listed in another schedule, or specifically named in this
18 schedule, this includes any substance that is structurally related to
19 fentanyl by one or more of the following modifications:
20 (A) Replacement of the phenyl portion of the phenethyl group by any
21 monocycle, whether or not further substituted in or on the monocycle;
22 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
23 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
24 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
25 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
26 (D) Replacement of the aniline ring with any aromatic monocycle
27 whether or not further substituted in or on the aromatic monocycle; or
28 (E) Replacement of the N-propionyl group by another acyl group.
29 (b) Any of the following opium derivatives, their salts, isomers,
30 and salts of isomers, unless specifically excepted, whenever the
31 existence of such salts, isomers, and salts of isomers is possible within
-5-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 the specific chemical designation:
2 (1) Acetorphine;
3 (2) Acetyldihydrocodeine;
4 (3) Benzylmorphine;
5 (4) Codeine methylbromide;
6 (5) Codeine-N-Oxide;
7 (6) Cyprenorphine;
8 (7) Desomorphine;
9 (8) Dihydromorphine;
10 (9) Drotebanol;
11 (10) Etorphine, except hydrochloride salt;
12 (11) Heroin;
13 (12) Hydromorphinol;
14 (13) Methyldesorphine;
15 (14) Methyldihydromorphine;
16 (15) Morphine methylbromide;
17 (16) Morphine methylsulfonate;
18 (17) Morphine-N-Oxide;
19 (18) Myrophine;
20 (19) Nicocodeine;
21 (20) Nicomorphine;
22 (21) Normorphine;
23 (22) Pholcodine; and
24 (23) Thebacon.
25 (c) Any material, compound, mixture, or preparation which contains
26 any quantity of the following hallucinogenic substances, their salts,
27 isomers, and salts of isomers, unless specifically excepted, whenever the
28 existence of such salts, isomers, and salts of isomers is possible within
29 the specific chemical designation, and, for purposes of this subdivision
30 only, isomer shall include the optical, position, and geometric isomers:
31 (1) Bufotenine. Trade and other names shall include, but are not
-6-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
2 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
3 dimethyltryptamine; and mappine;
4 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
5 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
6 methylphenethylamine; and 4-bromo-2,5-DMA;
7 (3) 4-methoxyamphetamine. Trade and other names shall include, but
8 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
9 paramethoxyamphetamine, PMA;
10 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
11 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
12 methylphenethylamine; DOM; and STP;
13 (5) Para-methoxymethamphetamine. Trade and other names shall
14 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
15 amine, PMMA, and 4-MMA;
16 (6) Ibogaine. Trade and other names shall include, but are not
17 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
18 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
19 iboga;
20 (7) Lysergic acid diethylamide;
21 (8) Marijuana;
22 (9) Mescaline;
23 (10) Methoxetamine (MXE);
24 (11) Peyote. Peyote shall mean all parts of the plant presently
25 classified botanically as Lophophora williamsii Lemaire, whether growing
26 or not, the seeds thereof, any extract from any part of such plant, and
27 every compound, manufacture, salts, derivative, mixture, or preparation
28 of such plant or its seeds or extracts;
29 (12) Psilocybin;
30 (13) Psilocyn;
31 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
-7-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 equivalents of the substances contained in the plant or in the resinous
2 extractives of cannabis, sp. or synthetic substances, derivatives, and
3 their isomers with similar chemical structure and pharmacological
4 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
5 and their optical isomers, excluding dronabinol in a drug product
6 approved by the federal Food and Drug Administration; Delta 6 cis or
7 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
8 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
9 of these substances is not internationally standardized, compounds of
10 these structures shall be included regardless of the numerical
11 designation of atomic positions covered. Tetrahydrocannabinols does not
12 include cannabidiol contained in a drug product approved by the federal
13 Food and Drug Administration;
14 (15) N-ethyl-3-piperidyl benzilate;
15 (16) N-methyl-3-piperidyl benzilate;
16 (17) Thiophene analog of phencyclidine. Trade and other names shall
17 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
18 2-thienyl analog of phencyclidine; TPCP; and TCP;
19 (18) Hashish or concentrated cannabis;
20 (19) Parahexyl. Trade and other names shall include, but are not
21 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
22 dibenzo(b,d)pyran; and Synhexyl;
23 (20) Ethylamine analog of phencyclidine. Trade and other names shall
24 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
25 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
26 cyclohexamine; and PCE;
27 (21) Pyrrolidine analog of phencyclidine. Trade and other names
28 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
29 pyrrolidine; PCPy; and PHP;
30 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
31 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
-8-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 alpha-ET; and AET;
2 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
3 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
4 (25) Alpha-methyltryptamine, which is also known as AMT;
5 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
6 Salvinorin A includes all parts of the plant presently classified
7 botanically as Salvia divinorum, whether growing or not, the seeds
8 thereof, any extract from any part of such plant, and every compound,
9 manufacture, derivative, mixture, or preparation of such plant, its
10 seeds, or its extracts, including salts, isomers, and salts of isomers
11 whenever the existence of such salts, isomers, and salts of isomers is
12 possible within the specific chemical designation;
13 (27) Any material, compound, mixture, or preparation containing any
14 quantity of synthetically produced cannabinoids as listed in subdivisions
15 (A) through (L) of this subdivision, including their salts, isomers,
16 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
17 unless specifically excepted elsewhere in this section. Since
18 nomenclature of these synthetically produced cannabinoids is not
19 internationally standardized and may continually evolve, these structures
20 or compounds of these structures shall be included under this
21 subdivision, regardless of their specific numerical designation of atomic
22 positions covered, so long as it can be determined through a recognized
23 method of scientific testing or analysis that the substance contains
24 properties that fit within one or more of the following categories:
25 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
26 contained in a plant of the genus cannabis (cannabis plant), as well as
27 synthetic equivalents of the substances contained in the plant, or in the
28 resinous extractives of cannabis, sp. and/or synthetic substances,
29 derivatives, and their isomers with similar chemical structure and
30 pharmacological activity such as the following: Delta 1 cis or trans
31 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
-9-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
2 tetrahydrocannabinol, and its optical isomers. This subdivision does not
3 include cannabidiol contained in a drug product approved by the federal
4 Food and Drug Administration;
5 (B) Naphthoylindoles: Any compound containing a 3-(1-
6 naphthoyl)indole structure with substitution at the nitrogen atom of the
7 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
8 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
9 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
10 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
11 tetrahydropyranylmethyl group, whether or not further substituted in or
12 on any of the listed ring systems to any extent;
13 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
14 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
15 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
16 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
17 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
18 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
19 tetrahydropyranylmethyl group, whether or not further substituted in or
20 on any of the listed ring systems to any extent;
21 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
22 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
23 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
24 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
25 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
27 tetrahydropyranylmethyl group, whether or not further substituted in or
28 on any of the listed ring systems to any extent;
29 (E) Naphthylideneindenes: Any compound containing a
30 naphthylideneindene structure with substitution at the 3-position of the
31 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
-10-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
2 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
4 tetrahydropyranylmethyl group, whether or not further substituted in or
5 on any of the listed ring systems to any extent;
6 (F) Phenylacetylindoles: Any compound containing a 3-
7 phenylacetylindole structure with substitution at the nitrogen atom of
8 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
9 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
10 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
12 tetrahydropyranylmethyl group, whether or not further substituted in or
13 on any of the listed ring systems to any extent;
14 (G) Cyclohexylphenols: Any compound containing a 2-(3-
15 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
16 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
17 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
18 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
19 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
20 tetrahydropyranylmethyl group, whether or not substituted in or on any of
21 the listed ring systems to any extent;
22 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
23 structure with substitution at the nitrogen atom of the indole ring by an
24 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
25 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
26 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
27 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
28 further substituted in or on any of the listed ring systems to any
29 extent;
30 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
31 structure with substitution at the nitrogen atom of the indole ring by an
-11-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
2 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
3 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
4 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
5 further substituted in or on any of the listed ring systems to any
6 extent;
7 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
8 tetramethylcyclopropanoylindole structure with substitution at the
9 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
10 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
11 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
13 tetrahydropyranylmethyl group, whether or not further substituted in or
14 on any of the listed ring systems to any extent;
15 (K) Indole carboxamides: Any compound containing a 1-indole-3-
16 carboxamide structure with substitution at the nitrogen atom of the
17 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
18 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
19 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
20 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
21 tetrahydropyranylmethyl group, substitution at the carboxamide group by
22 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
23 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
24 substituted in or on any of the listed ring systems to any extent or to
25 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
26 propionaldehyde groups to any extent;
27 (L) Indole carboxylates: Any compound containing a 1-indole-3-
28 carboxylate structure with substitution at the nitrogen atom of the
29 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
30 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
31 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
-12-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
2 tetrahydropyranylmethyl group, substitution at the carboxylate group by
3 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
4 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
5 substituted in or on any of the listed ring systems to any extent or to
6 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
7 propionaldehyde groups to any extent; and
8 (M) Any nonnaturally occurring substance, chemical compound,
9 mixture, or preparation, not specifically listed elsewhere in these
10 schedules and which is not approved for human consumption by the federal
11 Food and Drug Administration, containing or constituting a cannabinoid
12 receptor agonist as defined in section 28-401;
13 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
14 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
15 and salts of isomers, esters, and ethers, whenever the existence of such
16 isomers, esters, ethers, and salts is possible within the specific
17 chemical designation;
18 (29) Any material, compound, mixture, or preparation containing any
19 quantity of a substituted phenethylamine as listed in subdivisions (A)
20 through (C) of this subdivision, unless specifically excepted, listed in
21 another schedule, or specifically named in this schedule, that is
22 structurally derived from phenylethan-2-amine by substitution on the
23 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
24 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
25 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
26 or tetrahydropyran ring system; or by substitution with two fused ring
27 systems from any combination of the furan, tetrahydrofuran, or
28 tetrahydropyran ring systems, whether or not the compound is further
29 modified in any of the following ways:
30 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
31 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
-13-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
2 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
3 and including, but not limited to:
4 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
5 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
6 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
7 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
8 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
9 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
10 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
11 or 2,5-Dimethoxyphenethylamine;
12 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
13 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
14 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
15 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
16 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
17 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
18 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
19 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
20 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
21 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
22 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
23 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
24 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
25 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
26 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
27 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
28 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
29 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
30 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
31 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
-14-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
2 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
3 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
4 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
5 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
6 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
7 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
8 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
9 methoxybenzyl)phenethylamine;
10 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
11 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
12 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
13 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
14 which is also known as 2CB-5-hemiFLY;
15 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
16 yl)ethanamine, which is also known as 2C-B-FLY;
17 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
18 yl)ethanamine, which is also known as 2C-B-butterFLY;
19 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
20 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
21 NBOMe;
22 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
23 which is also known as bromo-benzodifuranylisopropylamine or bromo-
24 dragonFLY;
25 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
26 is also known as 2C-INBOH or 25I-NBOH;
27 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
28 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
29 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
30 as 5-APDB;
31 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
-15-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 known as 6-APDB;
2 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
3 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
4 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
5 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
6 known as 2C-T-7;
7 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
8 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
9 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
10 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
11 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
12 MDMA;
13 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
14 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
15 (xxxvii) 3,4,5-trimethoxy amphetamine; and
16 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
17 is also known as N-hydroxyMDA;
18 (30) Any material, compound, mixture, or preparation containing any
19 quantity of a substituted tryptamine unless specifically excepted, listed
20 in another schedule, or specifically named in this schedule, that is
21 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
22 known as tryptamine, by mono- or di-substitution of the amine nitrogen
23 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
24 in a cyclic structure whether or not the compound is further substituted
25 at the alpha position with an alkyl group or whether or not further
26 substituted on the indole ring to any extent with any alkyl, alkoxy,
27 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
28 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
29 DALT;
30 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
31 DMT or OAcetylpsilocin;
-16-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
2 HO-MET;
3 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
4 HO-DIPT;
5 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
6 5-MeOMiPT;
7 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
8 DMT;
9 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
10 MeO-DiPT;
11 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
12 DET; and
13 (I) Dimethyltryptamine, which is also known as DMT; and
14 (31)(A) Any substance containing any quantity of the following
15 materials, compounds, mixtures, or structures:
16 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
17 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
18 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
19 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
20 (v) Fluoromethcathinone, or FMC;
21 (vi) Naphthylpyrovalerone, or naphyrone; or
22 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
23 butylone; or
24 (B) Unless listed in another schedule, any substance which contains
25 any quantity of any material, compound, mixture, or structure, other than
26 bupropion, that is structurally derived by any means from 2-
27 aminopropan-1-one by substitution at the 1-position with either phenyl,
28 naphthyl, or thiophene ring systems, whether or not the compound is
29 further modified in any of the following ways:
30 (i) Substitution in the ring system to any extent with alkyl,
31 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
-17-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 whether or not further substituted in the ring system by one or more
2 other univalent substituents;
3 (ii) Substitution at the 3-position with an acyclic alkyl
4 substituent; or
5 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
6 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
7 structure.
8 (d) Unless specifically excepted or unless listed in another
9 schedule, any material, compound, mixture, or preparation which contains
10 any quantity of the following substances having a depressant effect on
11 the central nervous system, including its salts, isomers, and salts of
12 isomers whenever the existence of such salts, isomers, and salts of
13 isomers is possible within the specific chemical designation:
14 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
15 yl)amino]heptanoic acid, including its salts, isomers, and salts of
16 isomers;
17 (2) Mecloqualone;
18 (3) Methaqualone; and
19 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
20 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
21 Oxybate; and Sodium Oxybutyrate.
22 (e) Unless specifically excepted or unless listed in another
23 schedule, any material, compound, mixture, or preparation which contains
24 any quantity of the following substances having a stimulant effect on the
25 central nervous system, including its salts, isomers, and salts of
26 isomers:
27 (1) Fenethylline;
28 (2) N-ethylamphetamine;
29 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
30 dihydro-5-phenyl-2-oxazolamine;
31 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
-18-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
2 (5) Methcathinone, its salts, optical isomers, and salts of optical
3 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
4 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
5 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
6 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
7 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
8 phenyl-2-oxazolamine;
9 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
10 and N,N-alpha-trimethylphenethylamine;
11 (8) Benzylpiperazine, 1-benzylpiperazine;
12 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
13 methyl-5-(4-methylphenyl)-2-oxazolamine); and
14 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
15 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
16 isomers.
17 (f) Any controlled substance analogue to the extent intended for
18 human consumption.
19 Schedule II
20 (a) Any of the following substances except those narcotic drugs
21 listed in other schedules whether produced directly or indirectly by
22 extraction from substances of vegetable origin, independently by means of
23 chemical synthesis, or by combination of extraction and chemical
24 synthesis:
25 (1) Opium and opiate, and any salt, compound, derivative, or
26 preparation of opium or opiate, excluding apomorphine, buprenorphine,
27 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
28 naloxone, and naltrexone and their salts, but including the following:
29 (A) Raw opium;
30 (B) Opium extracts;
31 (C) Opium fluid;
-19-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (D) Powdered opium;
2 (E) Granulated opium;
3 (F) Tincture of opium;
4 (G) Codeine;
5 (H) Ethylmorphine;
6 (I) Etorphine hydrochloride;
7 (J) Hydrocodone;
8 (K) Hydromorphone;
9 (L) Metopon;
10 (M) Morphine;
11 (N) Oxycodone;
12 (O) Oxymorphone;
13 (P) Oripavine;
14 (Q) Thebaine; and
15 (R) Dihydroetorphine;
16 (2) Any salt, compound, derivative, or preparation thereof which is
17 chemically equivalent to or identical with any of the substances referred
18 to in subdivision (1) of this subdivision, except that these substances
19 shall not include the isoquinoline alkaloids of opium;
20 (3) Opium poppy and poppy straw;
21 (4) Coca leaves and any salt, compound, derivative, or preparation
22 of coca leaves, and any salt, compound, derivative, or preparation
23 thereof which is chemically equivalent to or identical with any of these
24 substances, including cocaine or ecgonine and its salts, optical isomers,
25 and salts of optical isomers, except that the substances shall not
26 include decocainized coca leaves or extractions which do not contain
27 cocaine or ecgonine; and
28 (5) Concentrate of poppy straw, the crude extract of poppy straw in
29 either liquid, solid, or powder form which contains the phenanthrene
30 alkaloids of the opium poppy.
31 (b) Unless specifically excepted or unless in another schedule any
-20-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 of the following opiates, including their isomers, esters, ethers, salts,
2 and salts of their isomers, esters, and ethers whenever the existence of
3 such isomers, esters, ethers, and salts is possible within the specific
4 chemical designation, dextrorphan excepted:
5 (1) Alphaprodine;
6 (2) Anileridine;
7 (3) Bezitramide;
8 (4) Diphenoxylate;
9 (5) Fentanyl;
10 (6) Isomethadone;
11 (7) Levomethorphan;
12 (8) Levorphanol;
13 (9) Metazocine;
14 (10) Methadone;
15 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
16 butane;
17 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
18 diphenylpropane-carboxylic acid;
19 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
20 (14) Oliceridine;
21 (15) Pethidine or meperidine;
22 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
23 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
24 carboxylate;
25 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
26 carboxylic acid;
27 (19) Phenazocine;
28 (20) Piminodine;
29 (21) Racemethorphan;
30 (22) Racemorphan;
31 (23) Dihydrocodeine;
-21-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (24) Bulk Propoxyphene in nondosage forms;
2 (25) Sufentanil;
3 (26) Alfentanil;
4 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
5 acetylmethadol, levomethadyl acetate, and LAAM;
6 (28) Carfentanil;
7 (29) Remifentanil;
8 (30) Tapentadol; and
9 (31) Thiafentanil.
10 (c) Any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a potential for abuse
12 associated with a stimulant effect on the central nervous system:
13 (1) Amphetamine, its salts, optical isomers, and salts of its
14 optical isomers;
15 (2) Phenmetrazine and its salts;
16 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
17 (4) Methylphenidate; and
18 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
19 (d) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substances having a potential for abuse
21 associated with a depressant effect on the central nervous system,
22 including their salts, isomers, and salts of isomers whenever the
23 existence of such salts, isomers, and salts of isomers is possible within
24 the specific chemical designations:
25 (1) Amobarbital;
26 (2) Secobarbital;
27 (3) Pentobarbital;
28 (4) Phencyclidine; and
29 (5) Glutethimide.
30 (e) Hallucinogenic substances known as:
31 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
-22-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
2 dibenzo(b,d)pyran-9-one; and
3 (2) Dronabinol in an oral solution in a drug product approved by the
4 federal Food and Drug Administration.
5 (f) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances:
8 (1) Immediate precursor to amphetamine and methamphetamine:
9 Phenylacetone. Trade and other names shall include, but are not limited
10 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
11 ketone;
12 (2) Immediate precursors to phencyclidine, PCP:
13 (A) 1-phenylcyclohexylamine; or
14 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
15 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
16 (ANPP); or .
17 (4) Tianeptine, its salts, isomers, and salts of isomers whenever
18 the existence of such salts, isomers, and salts of isomers is possible
19 within the specific chemical designation.
20 Schedule III
21 (a) Any material, compound, mixture, or preparation which contains
22 any quantity of the following substances having a potential for abuse
23 associated with a stimulant effect on the central nervous system,
24 including their salts, isomers, whether optical, position, or geometric,
25 and salts of such isomers whenever the existence of such salts, isomers,
26 and salts of isomers is possible within the specific chemical
27 designation:
28 (1) Benzphetamine;
29 (2) Chlorphentermine;
30 (3) Clortermine; and
31 (4) Phendimetrazine.
-23-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (b) Any material, compound, mixture, or preparation which contains
2 any quantity of the following substances having a potential for abuse
3 associated with a depressant effect on the central nervous system:
4 (1) Any substance which contains any quantity of a derivative of
5 barbituric acid or any salt of a derivative of barbituric acid, except
6 those substances which are specifically listed in other schedules of this
7 section;
8 (2) Aprobarbital;
9 (3) Butabarbital;
10 (4) Butalbital;
11 (5) Butethal;
12 (6) Butobarbital;
13 (7) Chlorhexadol;
14 (8) Embutramide;
15 (9) Lysergic acid;
16 (10) Lysergic acid amide;
17 (11) Methyprylon;
18 (12) Perampanel;
19 (13) Secbutabarbital;
20 (14) Sulfondiethylmethane;
21 (15) Sulfonethylmethane;
22 (16) Sulfonmethane;
23 (17) Nalorphine;
24 (18) Talbutal;
25 (19) Thiamylal;
26 (20) Thiopental;
27 (21) Vinbarbital;
28 (22) Any compound, mixture, or preparation containing amobarbital,
29 secobarbital, pentobarbital, or any salt thereof and one or more other
30 active medicinal ingredients which are not listed in any schedule;
31 (23) Any suppository dosage form containing amobarbital,
-24-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 secobarbital, pentobarbital, or any salt of any of these drugs and
2 approved by the federal Food and Drug Administration for marketing only
3 as a suppository;
4 (24) Any drug product containing gamma-hydroxybutyric acid,
5 including its salts, isomers, and salts of isomers, for which an
6 application is approved under section 505 of the Federal Food, Drug, and
7 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
8 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
9 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
10 cyclohexanone; and
11 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
12 names for a tiletamine-zolazepam combination product shall include, but
13 are not limited to: telazol. Trade or other names for tiletamine shall
14 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
15 cyclohexanone. Trade or other names for zolazepam shall include, but are
16 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
17 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
18 (c) Unless specifically excepted or unless listed in another
19 schedule:
20 (1) Any material, compound, mixture, or preparation containing
21 limited quantities of any of the following narcotic drugs, or any salts
22 calculated as the free anhydrous base or alkaloid, in limited quantities
23 as set forth below:
24 (A) Not more than one and eight-tenths grams of codeine per one
25 hundred milliliters or not more than ninety milligrams per dosage unit,
26 with an equal or greater quantity of an isoquinoline alkaloid of opium;
27 (B) Not more than one and eight-tenths grams of codeine per one
28 hundred milliliters or not more than ninety milligrams per dosage unit,
29 with one or more active, nonnarcotic ingredients in recognized
30 therapeutic amounts;
31 (C) Not more than one and eight-tenths grams of dihydrocodeine per
-25-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 one hundred milliliters or not more than ninety milligrams per dosage
2 unit, with one or more active, nonnarcotic ingredients in recognized
3 therapeutic amounts;
4 (D) Not more than three hundred milligrams of ethylmorphine per one
5 hundred milliliters or not more than fifteen milligrams per dosage unit,
6 with one or more active, nonnarcotic ingredients in recognized
7 therapeutic amounts;
8 (E) Not more than five hundred milligrams of opium per one hundred
9 milliliters or per one hundred grams, or not more than twenty-five
10 milligrams per dosage unit, with one or more active, nonnarcotic
11 ingredients in recognized therapeutic amounts; and
12 (F) Not more than fifty milligrams of morphine per one hundred
13 milliliters or per one hundred grams with one or more active, nonnarcotic
14 ingredients in recognized therapeutic amounts; and
15 (2) Any material, compound, mixture, or preparation containing any
16 of the following narcotic drug or its salts, as set forth below:
17 (A) Buprenorphine.
18 (d) Unless contained on the list of exempt anabolic steroids of the
19 Drug Enforcement Administration of the United States Department of
20 Justice as the list existed on January 31, 2022, any anabolic steroid,
21 which shall include any material, compound, mixture, or preparation
22 containing any quantity of the following substances, including its salts,
23 isomers, and salts of isomers whenever the existence of such salts of
24 isomers is possible within the specific chemical designation:
25 (1) 3-beta,17-dihydroxy-5a-androstane;
26 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
27 (3) 5-alpha-androstan-3,17-dione;
28 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
29 ene);
30 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
31 ene);
-26-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
2 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
3 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
4 (9) 4-androstenedione (androst-4-en-3,17-dione);
5 (10) 5-androstenedione (androst-5-en-3,17-dione);
6 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
7 hydroxyandrost-4-en-3-one);
8 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
9 (13) Boldione (androsta-1,4-diene-3,17-3-one);
10 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
11 en-3-one);
12 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
13 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
14 alpha-methyl-androst-1,4-dien-3-one);
15 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
16 en-17-beta-ol) (a.k.a. 'madol');
17 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
18 hydroxy-5-alpha-androst-1-en-3-one);
19 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
20 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
21 androstan-3-one);
22 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
23 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
24 dihydroxyandrost-4-en-3-one);
25 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
26 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
27 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
28 furazan);
29 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
30 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
31 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
-27-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 one);
2 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
3 one);
4 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
5 one);
6 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
7 dien-3-one);
8 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
9 ene);
10 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
11 beta-ol-3-one);
12 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
13 one);
14 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
15 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
16 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
17 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
18 hydroxy-17-beta-hydroxyestr-4-en-3-one);
19 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
20 dien-3-one);
21 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
22 trien-3-one);
23 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
24 en-3-one);
25 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
26 en-3-one);
27 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
28 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
29 methyl-1-testosterone');
30 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
31 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
-28-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
2 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
3 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
4 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
5 dione);
6 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
7 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
8 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
9 en-3-one);
10 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
11 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
12 one);
13 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
14 one);
15 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
16 androstan-3-one);
17 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
18 en-3-one);
19 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
20 hydroxy-[5-alpha]-androstan-3-one);
21 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
22 c]pyrazole);
23 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
24 androst-2-eno[3,2-c]-pyrazole);
25 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
26 one);
27 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
28 oic acid lactone);
29 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
30 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
31 hydroxygon-4,9,11-trien-3-one);
-29-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
2 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
3 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
4 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
5 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
6 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
7 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
8 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
9 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
10 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
11 beta-ol;
12 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
13 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
14 dione;
15 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
16 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
17 (78) 4-hydroxy-androst-4-ene-3,17-dione;
18 (79) 5 alpha-Androstan-3,6,17-trione;
19 (80) 6-bromo-androst-1,4-diene-3,17-dione;
20 (81) 6-bromo-androstan-3,17-dione;
21 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
22 (83) Delta 1-dihydrotestosterone;
23 (84) Estra-4,9,11-triene-3,17-dione; and
24 (85) Any salt, ester, or ether of a drug or substance described or
25 listed in this subdivision if the salt, ester, or ether promotes muscle
26 growth.
27 (e) Hallucinogenic substances known as:
28 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
29 gelatin capsule in a drug product approved by the federal Food and Drug
30 Administration. Some other names for dronabinol are (6aR-
31 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
-30-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
2 Schedule IV
3 (a) Any material, compound, mixture, or preparation which contains
4 any quantity of the following substances, including their salts, isomers,
5 and salts of isomers whenever the existence of such salts, isomers, and
6 salts of isomers is possible within the specific chemical designation:
7 (1) Barbital;
8 (2) Chloral betaine;
9 (3) Chloral hydrate;
10 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
11 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
12 water soluble esterified estrogens);
13 (5) Clonazepam;
14 (6) Clorazepate;
15 (7) Daridorexant;
16 (8) Diazepam;
17 (9) Ethchlorvynol;
18 (10) Ethinamate;
19 (11) Flurazepam;
20 (12) Mebutamate;
21 (13) Meprobamate;
22 (14) Methohexital;
23 (15) Methylphenobarbital;
24 (16) Oxazepam;
25 (17) Paraldehyde;
26 (18) Petrichloral;
27 (19) Phenobarbital;
28 (20) Prazepam;
29 (21) Alprazolam;
30 (22) Bromazepam;
31 (23) Camazepam;
-31-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (24) Clobazam;
2 (25) Clotiazepam;
3 (26) Cloxazolam;
4 (27) Delorazepam;
5 (28) Estazolam;
6 (29) Ethyl loflazepate;
7 (30) Fludiazepam;
8 (31) Flunitrazepam;
9 (32) Halazepam;
10 (33) Haloxazolam;
11 (34) Ketazolam;
12 (35) Loprazolam;
13 (36) Lorazepam;
14 (37) Lormetazepam;
15 (38) Medazepam;
16 (39) Nimetazepam;
17 (40) Nitrazepam;
18 (41) Nordiazepam;
19 (42) Oxazolam;
20 (43) Pinazepam;
21 (44) Temazepam;
22 (45) Tetrazepam;
23 (46) Triazolam;
24 (47) Midazolam;
25 (48) Quazepam;
26 (49) Zolpidem;
27 (50) Dichloralphenazone;
28 (51) Zaleplon;
29 (52) Zopiclone;
30 (53) Fospropofol;
31 (54) Alfaxalone;
-32-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (55) Suvorexant;
2 (56) Carisoprodol;
3 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
4 (58) Lemborexant;
5 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
6 (60) Remimazolam; and
7 (61) Serdexmethylphenidate.
8 (b) Any material, compound, mixture, or preparation which contains
9 any quantity of the following substance, including its salts, isomers,
10 whether optical, position, or geometric, and salts of such isomers,
11 whenever the existence of such salts, isomers, and salts of isomers is
12 possible: Fenfluramine.
13 (c) Unless specifically excepted or unless listed in another
14 schedule, any material, compound, mixture, or preparation which contains
15 any quantity of the following substances having a stimulant effect on the
16 central nervous system, including their salts, isomers, whether optical,
17 position, or geometric, and salts of such isomers whenever the existence
18 of such salts, isomers, and salts of isomers is possible within the
19 specific chemical designation:
20 (1) Diethylpropion;
21 (2) Phentermine;
22 (3) Pemoline, including organometallic complexes and chelates
23 thereof;
24 (4) Mazindol;
25 (5) Pipradrol;
26 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
27 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
28 (8) Fencamfamin;
29 (9) Fenproporex;
30 (10) Mefenorex;
31 (11) Modafinil; and
-33-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (12) Sibutramine.
2 (d) Unless specifically excepted or unless listed in another
3 schedule, any material, compound, mixture, or preparation which contains
4 any quantity of the following narcotic drugs, or their salts or isomers
5 calculated as the free anhydrous base or alkaloid, in limited quantities
6 as set forth below:
7 (1) Propoxyphene in manufactured dosage forms;
8 (2) Not more than one milligram of difenoxin and not less than
9 twenty-five micrograms of atropine sulfate per dosage unit; and
10 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
11 salts, optical and geometric isomers, and salts of these isomers to
12 include: Tramadol.
13 (e) Unless specifically excepted or unless listed in another
14 schedule, any material, compound, mixture, or preparation which contains
15 any quantity of the following substances substance, including their its
16 salts:
17 (1) Pentazocine; and
18 (2) Butorphanol (including its optical isomers).
19 (f) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substance substances, including its salts,
21 isomers, and salts of such isomers, whenever the existence of such salts,
22 isomers, and salts of isomers is possible: Lorcaserin.
23 (g)(1) Unless specifically excepted or unless listed in another
24 schedule, any material, compound, mixture, or preparation which contains
25 any quantity of the following substance, including its salts, optical
26 isomers, and salts of such optical isomers: Ephedrine.
27 (2) The following drug products containing ephedrine, its salts,
28 optical isomers, and salts of such optical isomers, are excepted from
29 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
30 counter, in an area not accessible to customers, or in a locked case so
31 that a customer needs assistance from an employee to access the drug
-34-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 product; (B) are sold by a person, eighteen years of age or older, in the
2 course of his or her employment to a customer eighteen years of age or
3 older with the following restrictions: No customer shall be allowed to
4 purchase, receive, or otherwise acquire more than three and six-tenths
5 grams of ephedrine base during a twenty-four-hour period; no customer
6 shall purchase, receive, or otherwise acquire more than nine grams of
7 ephedrine base during a thirty-day period; and the customer shall display
8 a valid driver's or operator's license, a Nebraska state identification
9 card, a military identification card, an alien registration card, or a
10 passport as proof of identification; (C) are labeled and marketed in a
11 manner consistent with the pertinent OTC Tentative Final or Final
12 Monograph; (D) are manufactured and distributed for legitimate medicinal
13 use in a manner that reduces or eliminates the likelihood of abuse; and
14 (E) are not marketed, advertised, or represented in any manner for the
15 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
16 high, heightened sexual performance, or increased muscle mass:
17 (i) Primatene Tablets; and
18 (ii) Bronkaid Dual Action Caplets.
19 Schedule V
20 (a) Any compound, mixture, or preparation containing any of the
21 following limited quantities of narcotic drugs or salts calculated as the
22 free anhydrous base or alkaloid, which shall include one or more
23 nonnarcotic active medicinal ingredients in sufficient proportion to
24 confer upon the compound, mixture, or preparation valuable medicinal
25 qualities other than those possessed by the narcotic drug alone:
26 (1) Not more than two hundred milligrams of codeine per one hundred
27 milliliters or per one hundred grams;
28 (2) Not more than one hundred milligrams of dihydrocodeine per one
29 hundred milliliters or per one hundred grams;
30 (3) Not more than one hundred milligrams of ethylmorphine per one
31 hundred milliliters or per one hundred grams;
-35-
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (4) Not more than two and five-tenths milligrams of diphenoxylate
2 and not less than twenty-five micrograms of atropine sulfate per dosage
3 unit;
4 (5) Not more than one hundred milligrams of opium per one hundred
5 milliliters or per one hundred grams; and
6 (6) Not more than five-tenths milligram of difenoxin and not less
7 than twenty-five micrograms of atropine sulfate per dosage unit.
8 (b) Unless specifically exempted or excluded or unless listed in
9 another schedule, any material, compound, mixture, or preparation which
10 contains any quantity of the following substances having a stimulant
11 effect on the central nervous system, including its salts, isomers, and
12 salts of isomers: Pyrovalerone.
13 (c) Unless specifically exempted or excluded or unless listed in
14 another schedule, any material, compound, mixture, or preparation which
15 contains any quantity of the following substances having a depressant
16 effect on the central nervous system, including its salts, isomers, and
17 salts of isomers:
18 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
19 acid ethyl ester);
20 (2) Ganaxolone;
21 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
22 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
23 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
24 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
25 salts;
26 (6) Cenobamate; and
27 (7) Lasmiditan.
28 Sec. 18. Original section 28-405, Revised Statutes Cumulative
29 Supplement, 2024, is repealed.
30 2. Renumber the remaining sections accordingly.
-36-
[DELETED: yR1S 1 S 2 R S C S22 T f a t s o c src o t l o e p o t D EA o t U S D o J a t leS0(1e s a s o i e a e u2s e w t e o s i e3e4(5(6(7k8(9(0(1(2(3(4(5(6(7A0L5C]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: ( A Np p 1p((pi( 1 ( i oi0( P 1 i1o2( A N3p4i5( A N6p i o i s a s7o8( B N9i0( B N1p i o i s a s2o3( B ( n N4p i o a5g6( 3 N7p i o a g i8s9( N0(1( T N7A0L5C]
[DELETED: p( P Np i o i s a s oi( U 3m(((0( A 3 4 c1b2(3(4(5(6(7(8(9(0(1(2y3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: (((((((((0(1(2(3( B ( n 1 e4p5( F s t i e e6s a s o i e a e U s7e l i a s o s n i t8s t i a s t i s r t9f0(1m2(3a4(5a6( R o t a r w a a m7w8(9( A o t f o d t s i0a s o i u s e w t1e7A0L5C]
[DELETED: t((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6a q o t f h s t s7i8e9t0o1( B T a o n s i b a n7A0L5C]
[DELETED: l t 3 3d N 5d( 4 T a o n si b a n l t 4m(a n l t 4 ap0( 4 T a o n s1i b a n l t 42m3( P T a o n s4i b a n l t 15a6( I T a o n s i b a n7l t 78m ( a ( i a T9i0(1(2(3(4( P P s m a p o t p p5c6o7e8o9(0(1(7A0L5C]
[DELETED: ee o c s o s s d at i w s c s a paa t o i e d i a d pa b t f F a D A D 6 c otoo t s i n i s c o0t s s b i r o t n1d2i3F4(5(6(7i829(0( P T a o n s i b a n1l t 32d3(4i b a n l t N (5p N6c7( P a o p T a o n8s i b a n l t 19p0(1M a 3 i7A0L5C]
[DELETED: a(((( S d o S A S d oS A i a p o t p p cb a S d w g o n t st a e f a p o s p a e cm d m o p o s p i0s1w2p3(4q5( t ( o t s i t s i6s7u s e e i t s S8n o t s p c i n9i0o c o t s s b i u t1s2p3m o s t o a t t s c4p5( T M t n6c7s8r e o c s a s s9d a t i w s c s a0p a s a t f D 1 c o t1t a t o i D 6 c o t7A0L5C]
[DELETED: ttiF( N A c c a 3ni r b a a h a h bc c 2 gc 1 10p 1 o1t2o3( N A c c a 1 H4y5o6c c 2 g7c 1 18p 1 o9t0o1( N A c c a 32n3p r b a a h a h b4c c 2 g5c 1 16p 1 o7t8o9( N A c c 0n1i r b a a h a h b7A0L5C]
[DELETED: c c 2 gc 1 1p 1 oto( P A c c a 3p s w s a t n a ot i r b a a h a h bc c 2 g0c 1 11p 1 o2t3o4( C A c c a 25h6t p r b a a h a h b7c c 2 g8c 1 19p 1 o0t1t2( B A c c a 33s4a h a h b c5c6p 1 17m o t g w o n8f s i o o a o t l r s t a9e0(1s7A0L5C]
[DELETED: a h c a h bc c 12m o t g w o nf s i o o a o t l r s t ae( T A c c a 3t s w s a tn a o t i r b a a h c0a h b c c 11m 2 12p 1 o3t4o5( I c A c c a 16c s w s a t n a o t7i r b a a h c a h8b c c 19p 2 10p 1 o1t2a a m b p a 13p4s5t a 1 p a b o6p7( I c A c c a 18c s w s a t n a o t9i r b a a h c a h0b c c 11p 2 17A0L5C]
[DELETED: p 1 ota a m b p a 1pst a 1 p a b op( A n o s c cm o p n s l e i t0s1F a D A c o c a c2r3( Z 14y i i i e e s5a6i e e a s i p w t s7c8(9q o a s p a l i s (0t1a s o s n i t s t i2s d f p b s o t3p r w a f m r f f r o 4f t r b s w t a g b5s6o7s f a c o t f t o8t r s w o n t c i f9m0( S o t p r b a h h a1t7A0L5C]
[DELETED: paa(a(a(a0(1o2(324(5a6( 2 w i a7k8( 2 w i9a0( 2 w i1a2( 2 w i a k3a4(5k6( 1 w i a7k8(9k0(1k7A0L5C]
[DELETED: ( 2mN( 2mN( Nw i a k a M o 3m0( 21m w i a k a 2 o223( 24w5( 2 [6y7( 28y9( N t0b w i a k a 21N2( 13w i a k a b o b4d5(6i7(8(9(0a1( 6 w i a7A0L5C]
[DELETED: k( 2 w i a k a 2 5d(( 2 w i ak((40(1( 3 w i a k a2M3( 3 w i a k4a5(6( n 4 w7i8(9q0i a s o s n i t s t i1s d f 2 w i a2k3w4i5a t a p w a a g o w o n f6s o t i r t a e w a a a7h8( 5 w i a k a 59D0(1D7A0L5C]
[DELETED: (H( 4 w i a k a 4H(5(D( 5 w i a k a 50M1(2D3(4( A s c a q o t f5m6(7(8(9(0(1(2( B o b o3b4(5a6b t i s d b a m f 27a8n o t r s w o n t c i9f0( S i t r s t a e w a1a a h h o h s7A0L5C]
[DELETED: w o n f s i t r s b o o mo( S a t 3 w a a as( S a t 2 n a w a ods( U s e o u l i as0a1t2i w t e o s s i a s o3i4( A 75y a i i s i a s o6i7(8(9(0h 4 4 A S1O2( U s e o u l i a3s4a5c n s i i s i a s o6i7(8(9( A a 2 o 40d1( C 2 a7A0L5C]
[DELETED: a(i S o n 2 a( 2 aN m me( ( a (p( N N0a1(2( 4 ( n 4 43m4( N - p5i i i s i a s o6i7( A c s a t t e i f8h9S0( A o t f s e t n d1l i o s w p d o i b2e3c s o b c o e a c4s5( O a o a a s c d o6p o o o o e a b7t b d n n8n9(0(1(7A0L5C]
[DELETED: (((((((((0(1(2(3(4(5(6(7c8t9s0(1(2o c l a a s c d o p3t4s5a s o o i e t t s s n6i d c l o e w d n c7c8(9e l s o p f w c t p0a1(7A0L5C]
[DELETED: oasc(((((0(1(2(3(4(5( M 46b7( M 28d9(0(1(2(3( P e4c5( P 16c7(8(9(0(1(7A0L5C]
[DELETED: (((( L w i a k a la((((0(1a q o t f s h a p f a2a3( A i s o i a s o i4o5(6(7(8(9(0a q o t f s h a p f a1a w a d e o t c n s2i t s i a s o i w t3e4t5(6(7(8(9(0(1( N A n f n (7A0L5C]
[DELETED: d 6d(f( U s e o u l i asa( I p t a a mP0t P P b m k a m b1k2(3(4(5(6(7( T i s i a s o i w8t9w0S1(2a q o t f s h a p f a3a w a s e o t c n s4i5a6a s o i i p w t s c7d8(9(0(1(7A0L5C]
[DELETED: (a q o t f s h a p f aa( A s w c a q o a d obts((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8( A c m o p c a9s0a1( A s d f c a7A0L5C]
[DELETED: s p o a s o a o t d aaa( A d p c g ai i s i a s o i f w aaC(n f k (0c1( T a z o a s t T o o2n3a4i b a n l t 25c6n l t 47t8( U s e o u l i a9s0( A m c m o p c1l2c3a4( N m t o a e g o c p o5h6w7( N m t o a e g o c p o8h9w o o m a n i i r0t1(7A0L5C]
[DELETED: o h m o n m t n m p du w o o m a n i i rt(hw o o m a n i i rt(m o p o h g o n m t t0m p d u w o o m a n1i2( N m t f m o m p o h3m4i5(6o7(8(9D E A o t U S D o0J1w s i a m c m o p2c3i a s o i w t e o s s o4i5(6(7(8( 1 (9e0( 1 (1e7A0L5C]
[DELETED: (((((( B (h((0(1e2(3( D (4a5( D (6e7( D ( '8h9(0( D (1a2(3( F (4d5( F ( (6a7( F (8f9(0(1( 4 (7A0L5C]
[DELETED: o( M (o( M (o( M (d(e0( M (1b2( M (3o4(5(6(7( 1 (8h9( M (0d1( M (2t3( M (4e5( M (6e7( 1 (8h ( '9m0(1(7A0L5C]
[DELETED: (((( 1 (d((( N ( 1e0(1( N (2o3( N (4o5( O (6a7( O (8e9( O (0h1( P (2c3( S (4a5( S (6o7( T (8o9(0( T ( 11h7A0L5C]
[DELETED: (((((((((0( 2 a 3 a a a1b2(3( 4 a b4d5(6(7(8(9(0(1(2(3(4(5l6g7(8(9g0A S o n f d a (1t7A0L5C]
[DELETED: (S(aas(((0( C b n i l (1h a c b o m ( a2w3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: ((((((((a q o t f s i i s i0w o p o g a s o s i1w2p3( U s e o u l i a4s5a6c7p8o s s i a s o i i p w t9s0(1(2( P i o c a c3t4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: (( U s e o u l i asaca(( N m t o m o d a n l tt0( 2 i1s o a g i a s o t i t2i3( U s e o u l i a4s5a6s7(8(9(0a1i2i3( U s e o u l i a4s5a q o t f s i i s o6i7( T f d p c e i s8o i a s o s o i a e f9s ( o S I i t ( a s b 0c1t a c n a f a e t a t d7A0L5C]
[DELETED: pcop r o o a m t t a sg o e b d a t p n cs p r o o a m t n g oeac0p1m c w t p O T F o F2M3u4(5i6h7(8(9S0( A c m o p c a o t1f2f a b o a w s i o o m3n a m i i s p t4c u t c m o p v m5q6(7m8(9h0( N m t o h m o e p o1h7A0L5C]
[DELETED: ( N m t t a f m o dau(m( N m t f m o d a n lt( U s e o e o u l ia0c a q o t f s h a s1e2s3( U s e o e o u l i4a5c a q o t f s h a d6e7s8( E (9a0(1(2(3( B (4b5s6(7(8S 1  O s 2 R S C9S027A0L5C]


================================================================================

Raw Text:
AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
AMENDMENTS TO LB230
(Amendments to AM381)
Introduced by Riepe, 12.
1 1. Insert the following new sections:
2 Sec. 16. Section 28-405, Revised Statutes Cumulative Supplement,
3 2024, is amended to read:
4 28-405 The following are the schedules of controlled substances
5 referred to in the Uniform Controlled Substances Act, unless specifically
6 contained on the list of exempted products of the Drug Enforcement
7 Administration of the United States Department of Justice as the list
8 existed on January 31, 2022:
9 Schedule I
10 (a) Any of the following opiates, including their isomers, esters,
11 ethers, salts, and salts of isomers, esters, and ethers, unless
12 specifically excepted, whenever the existence of such isomers, esters,
13 ethers, and salts is possible within the specific chemical designation:
14 (1) Acetylmethadol;
15 (2) Allylprodine;
16 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
17 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
18 (4) Alphameprodine;
19 (5) Alphamethadol;
20 (6) Benzethidine;
21 (7) Betacetylmethadol;
22 (8) Betameprodine;
23 (9) Betamethadol;
24 (10) Betaprodine;
25 (11) Clonitazene;
26 (12) Dextromoramide;
-1-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (13) Difenoxin;
2 (14) Diampromide;
3 (15) Diethylthiambutene;
4 (16) Dimenoxadol;
5 (17) Dimepheptanol;
6 (18) Dimethylthiambutene;
7 (19) Dioxaphetyl butyrate;
8 (20) Dipipanone;
9 (21) Ethylmethylthiambutene;
10 (22) Etonitazene;
11 (23) Etoxeridine;
12 (24) Furethidine;
13 (25) Hydroxypethidine;
14 (26) Ketobemidone;
15 (27) Levomoramide;
16 (28) Levophenacylmorphan;
17 (29) Morpheridine;
18 (30) Noracymethadol;
19 (31) Norlevorphanol;
20 (32) Normethadone;
21 (33) Norpipanone;
22 (34) Phenadoxone;
23 (35) Phenampromide;
24 (36) Phenomorphan;
25 (37) Phenoperidine;
26 (38) Piritramide;
27 (39) Proheptazine;
28 (40) Properidine;
29 (41) Propiram;
30 (42) Racemoramide;
31 (43) Trimeperidine;
-2-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
2 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
3 piperidine;
4 (45) Tilidine;
5 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
6 phenylpropanamide, its optical and geometric isomers, salts, and salts of
7 isomers;
8 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
9 isomers, salts, and salts of isomers;
10 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
11 optical isomers, salts, and salts of isomers;
12 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
13 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
14 isomers;
15 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
16 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
17 of isomers;
18 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
19 its optical isomers, salts, and salts of isomers;
20 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
21 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
22 of isomers;
23 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
24 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
25 geometric isomers, salts, and salts of isomers;
26 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
27 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
28 salts, and salts of isomers;
29 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
30 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
31 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
-3-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 propanamide, its optical isomers, salts, and salts of isomers;
2 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
3 piperidinyl)propanamide, its optical isomers, salts, and salts of
4 isomers;
5 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
6 methylbenzamide;
7 (59) 4-Fluoroisobutyryl Fentanyl;
8 (60) Acetyl Fentanyl;
9 (61) Acyrloylfentanyl;
10 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
11 benzamide;
12 (63) Butyryl fentanyl;
13 (64) Cyclopentyl fentanyl;
14 (65) Cyclopropyl fentanyl;
15 (66) Furanyl fentanyl;
16 (67) Isobutyryl fentanyl;
17 (68) Isotonitazene;
18 (69) Methoxyacetyl fentanyl;
19 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
20 (71) Tetrahydrofuranyl fentanyl;
21 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
22 yl) propionamide;
23 (73) Ocfentanil;
24 (74) Ortho-Fluorofentanyl;
25 (75) Para-chloroisobutyryl fentanyl;
26 (76) Para-Fluorobutyryl Fentanyl;
27 (77) Valeryl fentanyl;
28 (78) Phenyl Fentanyl;
29 (79) Para-Methylfentanyl;
30 (80) Thiofuranyl Fentanyl;
31 (81) Beta-methyl Fentanyl;
-4-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (82) Beta'-Phenyl Fentanyl;
2 (83) Crotonyl Fentanyl;
3 (84) 2'-Fluoro Ortho-Fluorofentanyl;
4 (85) 4'-Methyl Acetyl Fentanyl;
5 (86) Ortho-Fluorobutyryl Fentanyl;
6 (87) Ortho-Methyl Acetylfentanyl;
7 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
8 (89) Ortho-Fluoroacryl Fentanyl;
9 (90) Fentanyl Carbamate;
10 (91) Ortho-Fluoroisobutyryl Fentanyl;
11 (92) Para-Fluoro Furanyl Fentanyl;
12 (93) Para-Methoxybutyryl Fentanyl;
13 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
14 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
15 (95) Fentanyl-related substances, their isomers, esters, ethers,
16 salts and salts of isomers, esters, and ethers. Unless specifically
17 excepted, listed in another schedule, or specifically named in this
18 schedule, this includes any substance that is structurally related to
19 fentanyl by one or more of the following modifications:
20 (A) Replacement of the phenyl portion of the phenethyl group by any
21 monocycle, whether or not further substituted in or on the monocycle;
22 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
23 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
24 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
25 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
26 (D) Replacement of the aniline ring with any aromatic monocycle
27 whether or not further substituted in or on the aromatic monocycle; or
28 (E) Replacement of the N-propionyl group by another acyl group.
29 (b) Any of the following opium derivatives, their salts, isomers,
30 and salts of isomers, unless specifically excepted, whenever the
31 existence of such salts, isomers, and salts of isomers is possible within
-5-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 the specific chemical designation:
2 (1) Acetorphine;
3 (2) Acetyldihydrocodeine;
4 (3) Benzylmorphine;
5 (4) Codeine methylbromide;
6 (5) Codeine-N-Oxide;
7 (6) Cyprenorphine;
8 (7) Desomorphine;
9 (8) Dihydromorphine;
10 (9) Drotebanol;
11 (10) Etorphine, except hydrochloride salt;
12 (11) Heroin;
13 (12) Hydromorphinol;
14 (13) Methyldesorphine;
15 (14) Methyldihydromorphine;
16 (15) Morphine methylbromide;
17 (16) Morphine methylsulfonate;
18 (17) Morphine-N-Oxide;
19 (18) Myrophine;
20 (19) Nicocodeine;
21 (20) Nicomorphine;
22 (21) Normorphine;
23 (22) Pholcodine; and
24 (23) Thebacon.
25 (c) Any material, compound, mixture, or preparation which contains
26 any quantity of the following hallucinogenic substances, their salts,
27 isomers, and salts of isomers, unless specifically excepted, whenever the
28 existence of such salts, isomers, and salts of isomers is possible within
29 the specific chemical designation, and, for purposes of this subdivision
30 only, isomer shall include the optical, position, and geometric isomers:
31 (1) Bufotenine. Trade and other names shall include, but are not
-6-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
2 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
3 dimethyltryptamine; and mappine;
4 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
5 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
6 methylphenethylamine; and 4-bromo-2,5-DMA;
7 (3) 4-methoxyamphetamine. Trade and other names shall include, but
8 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
9 paramethoxyamphetamine, PMA;
10 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
11 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
12 methylphenethylamine; DOM; and STP;
13 (5) Para-methoxymethamphetamine. Trade and other names shall
14 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
15 amine, PMMA, and 4-MMA;
16 (6) Ibogaine. Trade and other names shall include, but are not
17 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
18 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
19 iboga;
20 (7) Lysergic acid diethylamide;
21 (8) Marijuana;
22 (9) Mescaline;
23 (10) Methoxetamine (MXE);
24 (11) Peyote. Peyote shall mean all parts of the plant presently
25 classified botanically as Lophophora williamsii Lemaire, whether growing
26 or not, the seeds thereof, any extract from any part of such plant, and
27 every compound, manufacture, salts, derivative, mixture, or preparation
28 of such plant or its seeds or extracts;
29 (12) Psilocybin;
30 (13) Psilocyn;
31 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
-7-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 equivalents of the substances contained in the plant or in the resinous
2 extractives of cannabis, sp. or synthetic substances, derivatives, and
3 their isomers with similar chemical structure and pharmacological
4 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
5 and their optical isomers, excluding dronabinol in a drug product
6 approved by the federal Food and Drug Administration; Delta 6 cis or
7 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
8 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
9 of these substances is not internationally standardized, compounds of
10 these structures shall be included regardless of the numerical
11 designation of atomic positions covered. Tetrahydrocannabinols does not
12 include cannabidiol contained in a drug product approved by the federal
13 Food and Drug Administration;
14 (15) N-ethyl-3-piperidyl benzilate;
15 (16) N-methyl-3-piperidyl benzilate;
16 (17) Thiophene analog of phencyclidine. Trade and other names shall
17 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
18 2-thienyl analog of phencyclidine; TPCP; and TCP;
19 (18) Hashish or concentrated cannabis;
20 (19) Parahexyl. Trade and other names shall include, but are not
21 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
22 dibenzo(b,d)pyran; and Synhexyl;
23 (20) Ethylamine analog of phencyclidine. Trade and other names shall
24 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
25 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
26 cyclohexamine; and PCE;
27 (21) Pyrrolidine analog of phencyclidine. Trade and other names
28 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
29 pyrrolidine; PCPy; and PHP;
30 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
31 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
-8-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 alpha-ET; and AET;
2 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
3 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
4 (25) Alpha-methyltryptamine, which is also known as AMT;
5 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
6 Salvinorin A includes all parts of the plant presently classified
7 botanically as Salvia divinorum, whether growing or not, the seeds
8 thereof, any extract from any part of such plant, and every compound,
9 manufacture, derivative, mixture, or preparation of such plant, its
10 seeds, or its extracts, including salts, isomers, and salts of isomers
11 whenever the existence of such salts, isomers, and salts of isomers is
12 possible within the specific chemical designation;
13 (27) Any material, compound, mixture, or preparation containing any
14 quantity of synthetically produced cannabinoids as listed in subdivisions
15 (A) through (L) of this subdivision, including their salts, isomers,
16 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
17 unless specifically excepted elsewhere in this section. Since
18 nomenclature of these synthetically produced cannabinoids is not
19 internationally standardized and may continually evolve, these structures
20 or compounds of these structures shall be included under this
21 subdivision, regardless of their specific numerical designation of atomic
22 positions covered, so long as it can be determined through a recognized
23 method of scientific testing or analysis that the substance contains
24 properties that fit within one or more of the following categories:
25 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
26 contained in a plant of the genus cannabis (cannabis plant), as well as
27 synthetic equivalents of the substances contained in the plant, or in the
28 resinous extractives of cannabis, sp. and/or synthetic substances,
29 derivatives, and their isomers with similar chemical structure and
30 pharmacological activity such as the following: Delta 1 cis or trans
31 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
-9-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
2 tetrahydrocannabinol, and its optical isomers. This subdivision does not
3 include cannabidiol contained in a drug product approved by the federal
4 Food and Drug Administration;
5 (B) Naphthoylindoles: Any compound containing a 3-(1-
6 naphthoyl)indole structure with substitution at the nitrogen atom of the
7 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
8 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
9 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
10 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
11 tetrahydropyranylmethyl group, whether or not further substituted in or
12 on any of the listed ring systems to any extent;
13 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
14 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
15 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
16 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
17 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
18 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
19 tetrahydropyranylmethyl group, whether or not further substituted in or
20 on any of the listed ring systems to any extent;
21 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
22 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
23 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
24 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
25 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
27 tetrahydropyranylmethyl group, whether or not further substituted in or
28 on any of the listed ring systems to any extent;
29 (E) Naphthylideneindenes: Any compound containing a
30 naphthylideneindene structure with substitution at the 3-position of the
31 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
-10-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
2 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
4 tetrahydropyranylmethyl group, whether or not further substituted in or
5 on any of the listed ring systems to any extent;
6 (F) Phenylacetylindoles: Any compound containing a 3-
7 phenylacetylindole structure with substitution at the nitrogen atom of
8 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
9 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
10 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
12 tetrahydropyranylmethyl group, whether or not further substituted in or
13 on any of the listed ring systems to any extent;
14 (G) Cyclohexylphenols: Any compound containing a 2-(3-
15 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
16 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
17 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
18 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
19 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
20 tetrahydropyranylmethyl group, whether or not substituted in or on any of
21 the listed ring systems to any extent;
22 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
23 structure with substitution at the nitrogen atom of the indole ring by an
24 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
25 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
26 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
27 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
28 further substituted in or on any of the listed ring systems to any
29 extent;
30 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
31 structure with substitution at the nitrogen atom of the indole ring by an
-11-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
2 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
3 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
4 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
5 further substituted in or on any of the listed ring systems to any
6 extent;
7 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
8 tetramethylcyclopropanoylindole structure with substitution at the
9 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
10 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
11 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
13 tetrahydropyranylmethyl group, whether or not further substituted in or
14 on any of the listed ring systems to any extent;
15 (K) Indole carboxamides: Any compound containing a 1-indole-3-
16 carboxamide structure with substitution at the nitrogen atom of the
17 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
18 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
19 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
20 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
21 tetrahydropyranylmethyl group, substitution at the carboxamide group by
22 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
23 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
24 substituted in or on any of the listed ring systems to any extent or to
25 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
26 propionaldehyde groups to any extent;
27 (L) Indole carboxylates: Any compound containing a 1-indole-3-
28 carboxylate structure with substitution at the nitrogen atom of the
29 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
30 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
31 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
-12-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
2 tetrahydropyranylmethyl group, substitution at the carboxylate group by
3 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
4 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
5 substituted in or on any of the listed ring systems to any extent or to
6 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
7 propionaldehyde groups to any extent; and
8 (M) Any nonnaturally occurring substance, chemical compound,
9 mixture, or preparation, not specifically listed elsewhere in these
10 schedules and which is not approved for human consumption by the federal
11 Food and Drug Administration, containing or constituting a cannabinoid
12 receptor agonist as defined in section 28-401;
13 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
14 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
15 and salts of isomers, esters, and ethers, whenever the existence of such
16 isomers, esters, ethers, and salts is possible within the specific
17 chemical designation;
18 (29) Any material, compound, mixture, or preparation containing any
19 quantity of a substituted phenethylamine as listed in subdivisions (A)
20 through (C) of this subdivision, unless specifically excepted, listed in
21 another schedule, or specifically named in this schedule, that is
22 structurally derived from phenylethan-2-amine by substitution on the
23 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
24 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
25 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
26 or tetrahydropyran ring system; or by substitution with two fused ring
27 systems from any combination of the furan, tetrahydrofuran, or
28 tetrahydropyran ring systems, whether or not the compound is further
29 modified in any of the following ways:
30 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
31 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
-13-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
2 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
3 and including, but not limited to:
4 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
5 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
6 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
7 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
8 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
9 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
10 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
11 or 2,5-Dimethoxyphenethylamine;
12 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
13 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
14 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
15 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
16 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
17 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
18 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
19 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
20 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
21 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
22 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
23 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
24 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
25 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
26 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
27 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
28 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
29 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
30 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
31 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
-14-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
2 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
3 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
4 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
5 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
6 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
7 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
8 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
9 methoxybenzyl)phenethylamine;
10 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
11 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
12 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
13 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
14 which is also known as 2CB-5-hemiFLY;
15 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
16 yl)ethanamine, which is also known as 2C-B-FLY;
17 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
18 yl)ethanamine, which is also known as 2C-B-butterFLY;
19 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
20 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
21 NBOMe;
22 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
23 which is also known as bromo-benzodifuranylisopropylamine or bromo-
24 dragonFLY;
25 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
26 is also known as 2C-INBOH or 25I-NBOH;
27 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
28 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
29 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
30 as 5-APDB;
31 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
-15-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 known as 6-APDB;
2 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
3 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
4 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
5 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
6 known as 2C-T-7;
7 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
8 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
9 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
10 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
11 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
12 MDMA;
13 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
14 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
15 (xxxvii) 3,4,5-trimethoxy amphetamine; and
16 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
17 is also known as N-hydroxyMDA;
18 (30) Any material, compound, mixture, or preparation containing any
19 quantity of a substituted tryptamine unless specifically excepted, listed
20 in another schedule, or specifically named in this schedule, that is
21 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
22 known as tryptamine, by mono- or di-substitution of the amine nitrogen
23 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
24 in a cyclic structure whether or not the compound is further substituted
25 at the alpha position with an alkyl group or whether or not further
26 substituted on the indole ring to any extent with any alkyl, alkoxy,
27 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
28 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
29 DALT;
30 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
31 DMT or OAcetylpsilocin;
-16-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
2 HO-MET;
3 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
4 HO-DIPT;
5 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
6 5-MeOMiPT;
7 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
8 DMT;
9 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
10 MeO-DiPT;
11 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
12 DET; and
13 (I) Dimethyltryptamine, which is also known as DMT; and
14 (31)(A) Any substance containing any quantity of the following
15 materials, compounds, mixtures, or structures:
16 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
17 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
18 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
19 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
20 (v) Fluoromethcathinone, or FMC;
21 (vi) Naphthylpyrovalerone, or naphyrone; or
22 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
23 butylone; or
24 (B) Unless listed in another schedule, any substance which contains
25 any quantity of any material, compound, mixture, or structure, other than
26 bupropion, that is structurally derived by any means from 2-
27 aminopropan-1-one by substitution at the 1-position with either phenyl,
28 naphthyl, or thiophene ring systems, whether or not the compound is
29 further modified in any of the following ways:
30 (i) Substitution in the ring system to any extent with alkyl,
31 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
-17-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 whether or not further substituted in the ring system by one or more
2 other univalent substituents;
3 (ii) Substitution at the 3-position with an acyclic alkyl
4 substituent; or
5 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
6 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
7 structure.
8 (d) Unless specifically excepted or unless listed in another
9 schedule, any material, compound, mixture, or preparation which contains
10 any quantity of the following substances having a depressant effect on
11 the central nervous system, including its salts, isomers, and salts of
12 isomers whenever the existence of such salts, isomers, and salts of
13 isomers is possible within the specific chemical designation:
14 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
15 yl)amino]heptanoic acid, including its salts, isomers, and salts of
16 isomers;
17 (2) Mecloqualone;
18 (3) Methaqualone; and
19 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
20 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
21 Oxybate; and Sodium Oxybutyrate.
22 (e) Unless specifically excepted or unless listed in another
23 schedule, any material, compound, mixture, or preparation which contains
24 any quantity of the following substances having a stimulant effect on the
25 central nervous system, including its salts, isomers, and salts of
26 isomers:
27 (1) Fenethylline;
28 (2) N-ethylamphetamine;
29 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
30 dihydro-5-phenyl-2-oxazolamine;
31 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
-18-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
2 (5) Methcathinone, its salts, optical isomers, and salts of optical
3 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
4 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
5 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
6 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
7 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
8 phenyl-2-oxazolamine;
9 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
10 and N,N-alpha-trimethylphenethylamine;
11 (8) Benzylpiperazine, 1-benzylpiperazine;
12 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
13 methyl-5-(4-methylphenyl)-2-oxazolamine); and
14 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
15 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
16 isomers.
17 (f) Any controlled substance analogue to the extent intended for
18 human consumption.
19 Schedule II
20 (a) Any of the following substances except those narcotic drugs
21 listed in other schedules whether produced directly or indirectly by
22 extraction from substances of vegetable origin, independently by means of
23 chemical synthesis, or by combination of extraction and chemical
24 synthesis:
25 (1) Opium and opiate, and any salt, compound, derivative, or
26 preparation of opium or opiate, excluding apomorphine, buprenorphine,
27 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
28 naloxone, and naltrexone and their salts, but including the following:
29 (A) Raw opium;
30 (B) Opium extracts;
31 (C) Opium fluid;
-19-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (D) Powdered opium;
2 (E) Granulated opium;
3 (F) Tincture of opium;
4 (G) Codeine;
5 (H) Ethylmorphine;
6 (I) Etorphine hydrochloride;
7 (J) Hydrocodone;
8 (K) Hydromorphone;
9 (L) Metopon;
10 (M) Morphine;
11 (N) Oxycodone;
12 (O) Oxymorphone;
13 (P) Oripavine;
14 (Q) Thebaine; and
15 (R) Dihydroetorphine;
16 (2) Any salt, compound, derivative, or preparation thereof which is
17 chemically equivalent to or identical with any of the substances referred
18 to in subdivision (1) of this subdivision, except that these substances
19 shall not include the isoquinoline alkaloids of opium;
20 (3) Opium poppy and poppy straw;
21 (4) Coca leaves and any salt, compound, derivative, or preparation
22 of coca leaves, and any salt, compound, derivative, or preparation
23 thereof which is chemically equivalent to or identical with any of these
24 substances, including cocaine or ecgonine and its salts, optical isomers,
25 and salts of optical isomers, except that the substances shall not
26 include decocainized coca leaves or extractions which do not contain
27 cocaine or ecgonine; and
28 (5) Concentrate of poppy straw, the crude extract of poppy straw in
29 either liquid, solid, or powder form which contains the phenanthrene
30 alkaloids of the opium poppy.
31 (b) Unless specifically excepted or unless in another schedule any
-20-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 of the following opiates, including their isomers, esters, ethers, salts,
2 and salts of their isomers, esters, and ethers whenever the existence of
3 such isomers, esters, ethers, and salts is possible within the specific
4 chemical designation, dextrorphan excepted:
5 (1) Alphaprodine;
6 (2) Anileridine;
7 (3) Bezitramide;
8 (4) Diphenoxylate;
9 (5) Fentanyl;
10 (6) Isomethadone;
11 (7) Levomethorphan;
12 (8) Levorphanol;
13 (9) Metazocine;
14 (10) Methadone;
15 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
16 butane;
17 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
18 diphenylpropane-carboxylic acid;
19 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
20 (14) Oliceridine;
21 (15) Pethidine or meperidine;
22 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
23 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
24 carboxylate;
25 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
26 carboxylic acid;
27 (19) Phenazocine;
28 (20) Piminodine;
29 (21) Racemethorphan;
30 (22) Racemorphan;
31 (23) Dihydrocodeine;
-21-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (24) Bulk Propoxyphene in nondosage forms;
2 (25) Sufentanil;
3 (26) Alfentanil;
4 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
5 acetylmethadol, levomethadyl acetate, and LAAM;
6 (28) Carfentanil;
7 (29) Remifentanil;
8 (30) Tapentadol; and
9 (31) Thiafentanil.
10 (c) Any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a potential for abuse
12 associated with a stimulant effect on the central nervous system:
13 (1) Amphetamine, its salts, optical isomers, and salts of its
14 optical isomers;
15 (2) Phenmetrazine and its salts;
16 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
17 (4) Methylphenidate; and
18 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
19 (d) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substances having a potential for abuse
21 associated with a depressant effect on the central nervous system,
22 including their salts, isomers, and salts of isomers whenever the
23 existence of such salts, isomers, and salts of isomers is possible within
24 the specific chemical designations:
25 (1) Amobarbital;
26 (2) Secobarbital;
27 (3) Pentobarbital;
28 (4) Phencyclidine; and
29 (5) Glutethimide.
30 (e) Hallucinogenic substances known as:
31 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
-22-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
2 dibenzo(b,d)pyran-9-one; and
3 (2) Dronabinol in an oral solution in a drug product approved by the
4 federal Food and Drug Administration.
5 (f) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances:
8 (1) Immediate precursor to amphetamine and methamphetamine:
9 Phenylacetone. Trade and other names shall include, but are not limited
10 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
11 ketone;
12 (2) Immediate precursors to phencyclidine, PCP:
13 (A) 1-phenylcyclohexylamine; or
14 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
15 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
16 (ANPP); or .
17 (4) Tianeptine, its salts, isomers, and salts of isomers whenever
18 the existence of such salts, isomers, and salts of isomers is possible
19 within the specific chemical designation.
20 Schedule III
21 (a) Any material, compound, mixture, or preparation which contains
22 any quantity of the following substances having a potential for abuse
23 associated with a stimulant effect on the central nervous system,
24 including their salts, isomers, whether optical, position, or geometric,
25 and salts of such isomers whenever the existence of such salts, isomers,
26 and salts of isomers is possible within the specific chemical
27 designation:
28 (1) Benzphetamine;
29 (2) Chlorphentermine;
30 (3) Clortermine; and
31 (4) Phendimetrazine.
-23-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (b) Any material, compound, mixture, or preparation which contains
2 any quantity of the following substances having a potential for abuse
3 associated with a depressant effect on the central nervous system:
4 (1) Any substance which contains any quantity of a derivative of
5 barbituric acid or any salt of a derivative of barbituric acid, except
6 those substances which are specifically listed in other schedules of this
7 section;
8 (2) Aprobarbital;
9 (3) Butabarbital;
10 (4) Butalbital;
11 (5) Butethal;
12 (6) Butobarbital;
13 (7) Chlorhexadol;
14 (8) Embutramide;
15 (9) Lysergic acid;
16 (10) Lysergic acid amide;
17 (11) Methyprylon;
18 (12) Perampanel;
19 (13) Secbutabarbital;
20 (14) Sulfondiethylmethane;
21 (15) Sulfonethylmethane;
22 (16) Sulfonmethane;
23 (17) Nalorphine;
24 (18) Talbutal;
25 (19) Thiamylal;
26 (20) Thiopental;
27 (21) Vinbarbital;
28 (22) Any compound, mixture, or preparation containing amobarbital,
29 secobarbital, pentobarbital, or any salt thereof and one or more other
30 active medicinal ingredients which are not listed in any schedule;
31 (23) Any suppository dosage form containing amobarbital,
-24-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 secobarbital, pentobarbital, or any salt of any of these drugs and
2 approved by the federal Food and Drug Administration for marketing only
3 as a suppository;
4 (24) Any drug product containing gamma-hydroxybutyric acid,
5 including its salts, isomers, and salts of isomers, for which an
6 application is approved under section 505 of the Federal Food, Drug, and
7 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
8 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
9 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
10 cyclohexanone; and
11 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
12 names for a tiletamine-zolazepam combination product shall include, but
13 are not limited to: telazol. Trade or other names for tiletamine shall
14 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
15 cyclohexanone. Trade or other names for zolazepam shall include, but are
16 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
17 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
18 (c) Unless specifically excepted or unless listed in another
19 schedule:
20 (1) Any material, compound, mixture, or preparation containing
21 limited quantities of any of the following narcotic drugs, or any salts
22 calculated as the free anhydrous base or alkaloid, in limited quantities
23 as set forth below:
24 (A) Not more than one and eight-tenths grams of codeine per one
25 hundred milliliters or not more than ninety milligrams per dosage unit,
26 with an equal or greater quantity of an isoquinoline alkaloid of opium;
27 (B) Not more than one and eight-tenths grams of codeine per one
28 hundred milliliters or not more than ninety milligrams per dosage unit,
29 with one or more active, nonnarcotic ingredients in recognized
30 therapeutic amounts;
31 (C) Not more than one and eight-tenths grams of dihydrocodeine per
-25-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 one hundred milliliters or not more than ninety milligrams per dosage
2 unit, with one or more active, nonnarcotic ingredients in recognized
3 therapeutic amounts;
4 (D) Not more than three hundred milligrams of ethylmorphine per one
5 hundred milliliters or not more than fifteen milligrams per dosage unit,
6 with one or more active, nonnarcotic ingredients in recognized
7 therapeutic amounts;
8 (E) Not more than five hundred milligrams of opium per one hundred
9 milliliters or per one hundred grams, or not more than twenty-five
10 milligrams per dosage unit, with one or more active, nonnarcotic
11 ingredients in recognized therapeutic amounts; and
12 (F) Not more than fifty milligrams of morphine per one hundred
13 milliliters or per one hundred grams with one or more active, nonnarcotic
14 ingredients in recognized therapeutic amounts; and
15 (2) Any material, compound, mixture, or preparation containing any
16 of the following narcotic drug or its salts, as set forth below:
17 (A) Buprenorphine.
18 (d) Unless contained on the list of exempt anabolic steroids of the
19 Drug Enforcement Administration of the United States Department of
20 Justice as the list existed on January 31, 2022, any anabolic steroid,
21 which shall include any material, compound, mixture, or preparation
22 containing any quantity of the following substances, including its salts,
23 isomers, and salts of isomers whenever the existence of such salts of
24 isomers is possible within the specific chemical designation:
25 (1) 3-beta,17-dihydroxy-5a-androstane;
26 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
27 (3) 5-alpha-androstan-3,17-dione;
28 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
29 ene);
30 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
31 ene);
-26-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
2 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
3 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
4 (9) 4-androstenedione (androst-4-en-3,17-dione);
5 (10) 5-androstenedione (androst-5-en-3,17-dione);
6 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
7 hydroxyandrost-4-en-3-one);
8 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
9 (13) Boldione (androsta-1,4-diene-3,17-3-one);
10 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
11 en-3-one);
12 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
13 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
14 alpha-methyl-androst-1,4-dien-3-one);
15 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
16 en-17-beta-ol) (a.k.a. 'madol');
17 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
18 hydroxy-5-alpha-androst-1-en-3-one);
19 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
20 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
21 androstan-3-one);
22 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
23 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
24 dihydroxyandrost-4-en-3-one);
25 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
26 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
27 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
28 furazan);
29 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
30 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
31 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
-27-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 one);
2 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
3 one);
4 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
5 one);
6 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
7 dien-3-one);
8 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
9 ene);
10 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
11 beta-ol-3-one);
12 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
13 one);
14 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
15 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
16 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
17 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
18 hydroxy-17-beta-hydroxyestr-4-en-3-one);
19 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
20 dien-3-one);
21 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
22 trien-3-one);
23 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
24 en-3-one);
25 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
26 en-3-one);
27 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
28 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
29 methyl-1-testosterone');
30 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
31 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
-28-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
2 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
3 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
4 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
5 dione);
6 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
7 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
8 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
9 en-3-one);
10 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
11 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
12 one);
13 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
14 one);
15 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
16 androstan-3-one);
17 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
18 en-3-one);
19 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
20 hydroxy-[5-alpha]-androstan-3-one);
21 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
22 c]pyrazole);
23 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
24 androst-2-eno[3,2-c]-pyrazole);
25 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
26 one);
27 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
28 oic acid lactone);
29 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
30 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
31 hydroxygon-4,9,11-trien-3-one);
-29-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
2 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
3 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
4 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
5 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
6 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
7 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
8 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
9 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
10 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
11 beta-ol;
12 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
13 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
14 dione;
15 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
16 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
17 (78) 4-hydroxy-androst-4-ene-3,17-dione;
18 (79) 5 alpha-Androstan-3,6,17-trione;
19 (80) 6-bromo-androst-1,4-diene-3,17-dione;
20 (81) 6-bromo-androstan-3,17-dione;
21 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
22 (83) Delta 1-dihydrotestosterone;
23 (84) Estra-4,9,11-triene-3,17-dione; and
24 (85) Any salt, ester, or ether of a drug or substance described or
25 listed in this subdivision if the salt, ester, or ether promotes muscle
26 growth.
27 (e) Hallucinogenic substances known as:
28 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
29 gelatin capsule in a drug product approved by the federal Food and Drug
30 Administration. Some other names for dronabinol are (6aR-
31 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
-30-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
2 Schedule IV
3 (a) Any material, compound, mixture, or preparation which contains
4 any quantity of the following substances, including their salts, isomers,
5 and salts of isomers whenever the existence of such salts, isomers, and
6 salts of isomers is possible within the specific chemical designation:
7 (1) Barbital;
8 (2) Chloral betaine;
9 (3) Chloral hydrate;
10 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
11 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
12 water soluble esterified estrogens);
13 (5) Clonazepam;
14 (6) Clorazepate;
15 (7) Daridorexant;
16 (8) Diazepam;
17 (9) Ethchlorvynol;
18 (10) Ethinamate;
19 (11) Flurazepam;
20 (12) Mebutamate;
21 (13) Meprobamate;
22 (14) Methohexital;
23 (15) Methylphenobarbital;
24 (16) Oxazepam;
25 (17) Paraldehyde;
26 (18) Petrichloral;
27 (19) Phenobarbital;
28 (20) Prazepam;
29 (21) Alprazolam;
30 (22) Bromazepam;
31 (23) Camazepam;
-31-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (24) Clobazam;
2 (25) Clotiazepam;
3 (26) Cloxazolam;
4 (27) Delorazepam;
5 (28) Estazolam;
6 (29) Ethyl loflazepate;
7 (30) Fludiazepam;
8 (31) Flunitrazepam;
9 (32) Halazepam;
10 (33) Haloxazolam;
11 (34) Ketazolam;
12 (35) Loprazolam;
13 (36) Lorazepam;
14 (37) Lormetazepam;
15 (38) Medazepam;
16 (39) Nimetazepam;
17 (40) Nitrazepam;
18 (41) Nordiazepam;
19 (42) Oxazolam;
20 (43) Pinazepam;
21 (44) Temazepam;
22 (45) Tetrazepam;
23 (46) Triazolam;
24 (47) Midazolam;
25 (48) Quazepam;
26 (49) Zolpidem;
27 (50) Dichloralphenazone;
28 (51) Zaleplon;
29 (52) Zopiclone;
30 (53) Fospropofol;
31 (54) Alfaxalone;
-32-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (55) Suvorexant;
2 (56) Carisoprodol;
3 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
4 (58) Lemborexant;
5 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
6 (60) Remimazolam; and
7 (61) Serdexmethylphenidate.
8 (b) Any material, compound, mixture, or preparation which contains
9 any quantity of the following substance, including its salts, isomers,
10 whether optical, position, or geometric, and salts of such isomers,
11 whenever the existence of such salts, isomers, and salts of isomers is
12 possible: Fenfluramine.
13 (c) Unless specifically excepted or unless listed in another
14 schedule, any material, compound, mixture, or preparation which contains
15 any quantity of the following substances having a stimulant effect on the
16 central nervous system, including their salts, isomers, whether optical,
17 position, or geometric, and salts of such isomers whenever the existence
18 of such salts, isomers, and salts of isomers is possible within the
19 specific chemical designation:
20 (1) Diethylpropion;
21 (2) Phentermine;
22 (3) Pemoline, including organometallic complexes and chelates
23 thereof;
24 (4) Mazindol;
25 (5) Pipradrol;
26 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
27 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
28 (8) Fencamfamin;
29 (9) Fenproporex;
30 (10) Mefenorex;
31 (11) Modafinil; and
-33-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (12) Sibutramine.
2 (d) Unless specifically excepted or unless listed in another
3 schedule, any material, compound, mixture, or preparation which contains
4 any quantity of the following narcotic drugs, or their salts or isomers
5 calculated as the free anhydrous base or alkaloid, in limited quantities
6 as set forth below:
7 (1) Propoxyphene in manufactured dosage forms;
8 (2) Not more than one milligram of difenoxin and not less than
9 twenty-five micrograms of atropine sulfate per dosage unit; and
10 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
11 salts, optical and geometric isomers, and salts of these isomers to
12 include: Tramadol.
13 (e) Unless specifically excepted or unless listed in another
14 schedule, any material, compound, mixture, or preparation which contains
15 any quantity of the following substances substance, including their its
16 salts:
17 (1) Pentazocine; and
18 (2) Butorphanol (including its optical isomers).
19 (f) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substance substances, including its salts,
21 isomers, and salts of such isomers, whenever the existence of such salts,
22 isomers, and salts of isomers is possible: Lorcaserin.
23 (g)(1) Unless specifically excepted or unless listed in another
24 schedule, any material, compound, mixture, or preparation which contains
25 any quantity of the following substance, including its salts, optical
26 isomers, and salts of such optical isomers: Ephedrine.
27 (2) The following drug products containing ephedrine, its salts,
28 optical isomers, and salts of such optical isomers, are excepted from
29 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
30 counter, in an area not accessible to customers, or in a locked case so
31 that a customer needs assistance from an employee to access the drug
-34-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 product; (B) are sold by a person, eighteen years of age or older, in the
2 course of his or her employment to a customer eighteen years of age or
3 older with the following restrictions: No customer shall be allowed to
4 purchase, receive, or otherwise acquire more than three and six-tenths
5 grams of ephedrine base during a twenty-four-hour period; no customer
6 shall purchase, receive, or otherwise acquire more than nine grams of
7 ephedrine base during a thirty-day period; and the customer shall display
8 a valid driver's or operator's license, a Nebraska state identification
9 card, a military identification card, an alien registration card, or a
10 passport as proof of identification; (C) are labeled and marketed in a
11 manner consistent with the pertinent OTC Tentative Final or Final
12 Monograph; (D) are manufactured and distributed for legitimate medicinal
13 use in a manner that reduces or eliminates the likelihood of abuse; and
14 (E) are not marketed, advertised, or represented in any manner for the
15 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
16 high, heightened sexual performance, or increased muscle mass:
17 (i) Primatene Tablets; and
18 (ii) Bronkaid Dual Action Caplets.
19 Schedule V
20 (a) Any compound, mixture, or preparation containing any of the
21 following limited quantities of narcotic drugs or salts calculated as the
22 free anhydrous base or alkaloid, which shall include one or more
23 nonnarcotic active medicinal ingredients in sufficient proportion to
24 confer upon the compound, mixture, or preparation valuable medicinal
25 qualities other than those possessed by the narcotic drug alone:
26 (1) Not more than two hundred milligrams of codeine per one hundred
27 milliliters or per one hundred grams;
28 (2) Not more than one hundred milligrams of dihydrocodeine per one
29 hundred milliliters or per one hundred grams;
30 (3) Not more than one hundred milligrams of ethylmorphine per one
31 hundred milliliters or per one hundred grams;
-35-

AM577 AM577
LB230 LB230
CSO - 03/07/2025 CSO - 03/07/2025
1 (4) Not more than two and five-tenths milligrams of diphenoxylate
2 and not less than twenty-five micrograms of atropine sulfate per dosage
3 unit;
4 (5) Not more than one hundred milligrams of opium per one hundred
5 milliliters or per one hundred grams; and
6 (6) Not more than five-tenths milligram of difenoxin and not less
7 than twenty-five micrograms of atropine sulfate per dosage unit.
8 (b) Unless specifically exempted or excluded or unless listed in
9 another schedule, any material, compound, mixture, or preparation which
10 contains any quantity of the following substances having a stimulant
11 effect on the central nervous system, including its salts, isomers, and
12 salts of isomers: Pyrovalerone.
13 (c) Unless specifically exempted or excluded or unless listed in
14 another schedule, any material, compound, mixture, or preparation which
15 contains any quantity of the following substances having a depressant
16 effect on the central nervous system, including its salts, isomers, and
17 salts of isomers:
18 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
19 acid ethyl ester);
20 (2) Ganaxolone;
21 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
22 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
23 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
24 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
25 salts;
26 (6) Cenobamate; and
27 (7) Lasmiditan.
28 Sec. 18. Original section 28-405, Revised Statutes Cumulative
29 Supplement, 2024, is repealed.
30 2. Renumber the remaining sections accordingly.
-36-

[DELETED: yR1S 1 S 2 R S C S22 T f a t s o c src o t l o e p o t D EA o t U S D o J a t leS0(1e s a s o i e a e u2s e w t e o s i e3e4(5(6(7k8(9(0(1(2(3(4(5(6(7A0L5C]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: ( A Np p 1p((pi( 1 ( i oi0( P 1 i1o2( A N3p4i5( A N6p i o i s a s7o8( B N9i0( B N1p i o i s a s2o3( B ( n N4p i o a5g6( 3 N7p i o a g i8s9( N0(1( T N7A0L5C]
[DELETED: p( P Np i o i s a s oi( U 3m(((0( A 3 4 c1b2(3(4(5(6(7(8(9(0(1(2y3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: (((((((((0(1(2(3( B ( n 1 e4p5( F s t i e e6s a s o i e a e U s7e l i a s o s n i t8s t i a s t i s r t9f0(1m2(3a4(5a6( R o t a r w a a m7w8(9( A o t f o d t s i0a s o i u s e w t1e7A0L5C]
[DELETED: t((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6a q o t f h s t s7i8e9t0o1( B T a o n s i b a n7A0L5C]
[DELETED: l t 3 3d N 5d( 4 T a o n si b a n l t 4m(a n l t 4 ap0( 4 T a o n s1i b a n l t 42m3( P T a o n s4i b a n l t 15a6( I T a o n s i b a n7l t 78m ( a ( i a T9i0(1(2(3(4( P P s m a p o t p p5c6o7e8o9(0(1(7A0L5C]
[DELETED: ee o c s o s s d at i w s c s a paa t o i e d i a d pa b t f F a D A D 6 c otoo t s i n i s c o0t s s b i r o t n1d2i3F4(5(6(7i829(0( P T a o n s i b a n1l t 32d3(4i b a n l t N (5p N6c7( P a o p T a o n8s i b a n l t 19p0(1M a 3 i7A0L5C]
[DELETED: a(((( S d o S A S d oS A i a p o t p p cb a S d w g o n t st a e f a p o s p a e cm d m o p o s p i0s1w2p3(4q5( t ( o t s i t s i6s7u s e e i t s S8n o t s p c i n9i0o c o t s s b i u t1s2p3m o s t o a t t s c4p5( T M t n6c7s8r e o c s a s s9d a t i w s c s a0p a s a t f D 1 c o t1t a t o i D 6 c o t7A0L5C]
[DELETED: ttiF( N A c c a 3ni r b a a h a h bc c 2 gc 1 10p 1 o1t2o3( N A c c a 1 H4y5o6c c 2 g7c 1 18p 1 o9t0o1( N A c c a 32n3p r b a a h a h b4c c 2 g5c 1 16p 1 o7t8o9( N A c c 0n1i r b a a h a h b7A0L5C]
[DELETED: c c 2 gc 1 1p 1 oto( P A c c a 3p s w s a t n a ot i r b a a h a h bc c 2 g0c 1 11p 1 o2t3o4( C A c c a 25h6t p r b a a h a h b7c c 2 g8c 1 19p 1 o0t1t2( B A c c a 33s4a h a h b c5c6p 1 17m o t g w o n8f s i o o a o t l r s t a9e0(1s7A0L5C]
[DELETED: a h c a h bc c 12m o t g w o nf s i o o a o t l r s t ae( T A c c a 3t s w s a tn a o t i r b a a h c0a h b c c 11m 2 12p 1 o3t4o5( I c A c c a 16c s w s a t n a o t7i r b a a h c a h8b c c 19p 2 10p 1 o1t2a a m b p a 13p4s5t a 1 p a b o6p7( I c A c c a 18c s w s a t n a o t9i r b a a h c a h0b c c 11p 2 17A0L5C]
[DELETED: p 1 ota a m b p a 1pst a 1 p a b op( A n o s c cm o p n s l e i t0s1F a D A c o c a c2r3( Z 14y i i i e e s5a6i e e a s i p w t s7c8(9q o a s p a l i s (0t1a s o s n i t s t i2s d f p b s o t3p r w a f m r f f r o 4f t r b s w t a g b5s6o7s f a c o t f t o8t r s w o n t c i f9m0( S o t p r b a h h a1t7A0L5C]
[DELETED: paa(a(a(a0(1o2(324(5a6( 2 w i a7k8( 2 w i9a0( 2 w i1a2( 2 w i a k3a4(5k6( 1 w i a7k8(9k0(1k7A0L5C]
[DELETED: ( 2mN( 2mN( Nw i a k a M o 3m0( 21m w i a k a 2 o223( 24w5( 2 [6y7( 28y9( N t0b w i a k a 21N2( 13w i a k a b o b4d5(6i7(8(9(0a1( 6 w i a7A0L5C]
[DELETED: k( 2 w i a k a 2 5d(( 2 w i ak((40(1( 3 w i a k a2M3( 3 w i a k4a5(6( n 4 w7i8(9q0i a s o s n i t s t i1s d f 2 w i a2k3w4i5a t a p w a a g o w o n f6s o t i r t a e w a a a7h8( 5 w i a k a 59D0(1D7A0L5C]
[DELETED: (H( 4 w i a k a 4H(5(D( 5 w i a k a 50M1(2D3(4( A s c a q o t f5m6(7(8(9(0(1(2( B o b o3b4(5a6b t i s d b a m f 27a8n o t r s w o n t c i9f0( S i t r s t a e w a1a a h h o h s7A0L5C]
[DELETED: w o n f s i t r s b o o mo( S a t 3 w a a as( S a t 2 n a w a ods( U s e o u l i as0a1t2i w t e o s s i a s o3i4( A 75y a i i s i a s o6i7(8(9(0h 4 4 A S1O2( U s e o u l i a3s4a5c n s i i s i a s o6i7(8(9( A a 2 o 40d1( C 2 a7A0L5C]
[DELETED: a(i S o n 2 a( 2 aN m me( ( a (p( N N0a1(2( 4 ( n 4 43m4( N - p5i i i s i a s o6i7( A c s a t t e i f8h9S0( A o t f s e t n d1l i o s w p d o i b2e3c s o b c o e a c4s5( O a o a a s c d o6p o o o o e a b7t b d n n8n9(0(1(7A0L5C]
[DELETED: (((((((((0(1(2(3(4(5(6(7c8t9s0(1(2o c l a a s c d o p3t4s5a s o o i e t t s s n6i d c l o e w d n c7c8(9e l s o p f w c t p0a1(7A0L5C]
[DELETED: oasc(((((0(1(2(3(4(5( M 46b7( M 28d9(0(1(2(3( P e4c5( P 16c7(8(9(0(1(7A0L5C]
[DELETED: (((( L w i a k a la((((0(1a q o t f s h a p f a2a3( A i s o i a s o i4o5(6(7(8(9(0a q o t f s h a p f a1a w a d e o t c n s2i t s i a s o i w t3e4t5(6(7(8(9(0(1( N A n f n (7A0L5C]
[DELETED: d 6d(f( U s e o u l i asa( I p t a a mP0t P P b m k a m b1k2(3(4(5(6(7( T i s i a s o i w8t9w0S1(2a q o t f s h a p f a3a w a s e o t c n s4i5a6a s o i i p w t s c7d8(9(0(1(7A0L5C]
[DELETED: (a q o t f s h a p f aa( A s w c a q o a d obts((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8( A c m o p c a9s0a1( A s d f c a7A0L5C]
[DELETED: s p o a s o a o t d aaa( A d p c g ai i s i a s o i f w aaC(n f k (0c1( T a z o a s t T o o2n3a4i b a n l t 25c6n l t 47t8( U s e o u l i a9s0( A m c m o p c1l2c3a4( N m t o a e g o c p o5h6w7( N m t o a e g o c p o8h9w o o m a n i i r0t1(7A0L5C]
[DELETED: o h m o n m t n m p du w o o m a n i i rt(hw o o m a n i i rt(m o p o h g o n m t t0m p d u w o o m a n1i2( N m t f m o m p o h3m4i5(6o7(8(9D E A o t U S D o0J1w s i a m c m o p2c3i a s o i w t e o s s o4i5(6(7(8( 1 (9e0( 1 (1e7A0L5C]
[DELETED: (((((( B (h((0(1e2(3( D (4a5( D (6e7( D ( '8h9(0( D (1a2(3( F (4d5( F ( (6a7( F (8f9(0(1( 4 (7A0L5C]
[DELETED: o( M (o( M (o( M (d(e0( M (1b2( M (3o4(5(6(7( 1 (8h9( M (0d1( M (2t3( M (4e5( M (6e7( 1 (8h ( '9m0(1(7A0L5C]
[DELETED: (((( 1 (d((( N ( 1e0(1( N (2o3( N (4o5( O (6a7( O (8e9( O (0h1( P (2c3( S (4a5( S (6o7( T (8o9(0( T ( 11h7A0L5C]
[DELETED: (((((((((0( 2 a 3 a a a1b2(3( 4 a b4d5(6(7(8(9(0(1(2(3(4(5l6g7(8(9g0A S o n f d a (1t7A0L5C]
[DELETED: (S(aas(((0( C b n i l (1h a c b o m ( a2w3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: ((((((((a q o t f s i i s i0w o p o g a s o s i1w2p3( U s e o u l i a4s5a6c7p8o s s i a s o i i p w t9s0(1(2( P i o c a c3t4(5(6(7(8(9(0(1(7A0L5C]
[DELETED: (( U s e o u l i asaca(( N m t o m o d a n l tt0( 2 i1s o a g i a s o t i t2i3( U s e o u l i a4s5a6s7(8(9(0a1i2i3( U s e o u l i a4s5a q o t f s i i s o6i7( T f d p c e i s8o i a s o s o i a e f9s ( o S I i t ( a s b 0c1t a c n a f a e t a t d7A0L5C]
[DELETED: pcop r o o a m t t a sg o e b d a t p n cs p r o o a m t n g oeac0p1m c w t p O T F o F2M3u4(5i6h7(8(9S0( A c m o p c a o t1f2f a b o a w s i o o m3n a m i i s p t4c u t c m o p v m5q6(7m8(9h0( N m t o h m o e p o1h7A0L5C]
[DELETED: ( N m t t a f m o dau(m( N m t f m o d a n lt( U s e o e o u l ia0c a q o t f s h a s1e2s3( U s e o e o u l i4a5c a q o t f s h a d6e7s8( E (9a0(1(2(3( B (4b5s6(7(8S 1  O s 2 R S C9S027A0L5C]